Evaluación quirúrgica de la linfadenectomía pélvica por laparoscopia en el tratamiento de neoplasias ginecológicas

  1. Gorostiaga, Alvaro 1
  2. Villegas, Itziar 1
  3. José Quílez 1
  4. Rui-Wamba, María Jesús 1
  5. Arriba, Tania 1
  6. Ibarrola, Rafael 1
  1. 1 Centro de Ginecología y Medicina Fetal (CEGYMF), Bilbao
Journal:
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

ISSN: 0304-4858,  2173-2302

Year of publication: 2012

Volume: 109

Issue: 4

Pages: 129-134

Type: Article

DOI: 10.1016/J.GMB.2012.06.001 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

Sustainable development goals

Abstract

IntroductionNowadays, the approach to gynecological malignancies is surgical and pelvic lymphadenectomy is needed for staging. To do this, laparoscopy is becoming the gold standard. However, in our environment, this modality is still restricted to large university hospitals.Material and methodsWe performed a retrospective review of 26 pelvic lymphadenectomies performed at the Centro de Ginecología y Medicina Fetal in Bilbao, Basque Country, Spain, to investigate its surgical results and applicability.ResultsThe mean surgical time was 90min (70-135min) and the mean number of nodes excised was 10.1 (2-17), with only one case of positive pelvic node. The mean time till discharge from the hospital was 2.17 days (2-3). The conversion rate to laparotomy was 0%, if patients who required laparotomy for other reasons during the oncologic intervention were excluded. There were no major complications and the rate of minor complications was low (11.53%).ConclusionsLaparoscopic pelvic lymphadenectomy is a safe and feasible procedure and is currently the gold standard for pelvic node excision in gynecologic malignancies.

€ View funding

Funding information

Dr. Inker reports funding to Tufts Medical Center for research and contracts with the National Institutes of Health (NIH), National Kidney Foundation (NKF), Retrophin, Omeros, Reata Pharmaceuticals, and Dialysis Clinic, Inc. She has consulting agreements with Tricida Inc. and Omeros Corp. Tufts Medical Center, John Hopkins University and Metabolon Inc. have a collaboration agreement to develop a product to estimate GFR from a panel of markers. Dr. Levey reports grants from the NIH and the NKF during the conduct of the study, and funding from Siemens outside of the submitted work. Dr. Coresh has grants from the NIH and the NKF related and unrelated to this research. Dr. Inker, Dr. Levey, and Dr. Coresh have a patent Precise estimation of GFR from multiple biomarkers pending to Dr. Coresh, Dr. Inker, and Dr. Levey; and Tufts Medical Center, John Hopkins University, and Metabolon Inc. have a collaboration agreement to develop a product to estimate GFR from a panel of markers. Dr. Heerspink reports grants and other from Abbvie, other from Astellas, grants and other from AstraZeneca, grants and other from Boehringer Ingelheim, grants and other from Janssen, other from Fresenius, other from Gilead, and other from Merck, outside of the submitted work. Dr. Wanner reports personal fees from Boehringer Ingelheim during the conduct of the study, and personal fees from Lilly, personal fees from AstraZeneca, and personal fees from MSD outside of the submitted work. Dr. Floege has received consultancy honoraria and/or speaker fees from Alnylam, Amgen, Bayer, Calliditas, Chugai, Fresenius, Omeros Corp., and Vifor. Dr. Perkovic reports personal fees for Advisory Boards or Scientific Presentations from Retrophin, Janssen, Merck, and Servier. He has served on Steering Committees for trials funded by Abbvie, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Pfizer; and participated in Scientific Presentations/Advisory boards with Abbvie, Astellas, Astra Zeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Dimetrix, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Sanofi, Tricida, and Vitae, with fees paid to his institution. Dr. Vonesh served as a paid biostatistics consultant for the NKF for the expressed purpose of developing statistical models for use in the estimation and comparison of GFR slopes as a surrogate end point in CKD randomized, controlled trials. He is also serving as a biostatistics consultant to Prometic and Tricida, Inc., in which some of the work entails consulting on the design and analysis of clinical trials in patients with CKD. Dr. Greene reports grants from the NKF during the conduct of the study, and personal fees from DURECT Corporation, Janssen Pharmaceuticals, and Pfizer Inc., outside of the submitted work. Dr. Beck, Dr. Gansevoort, Dr. Ying, Dr. Tighiouart, Dr. Li, and Dr. Simon have no conflicts to report.

Funders

Data source: Dialnet